BIBW 2992 in Patients With Advanced Solid Tumors
NCT02171650 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7
Last updated 2025-01-23
Summary
The primary objective was to collect safety data for BIBW 2992.
Conditions
- Neoplasms
Interventions
- DRUG
-
BIBW 2992
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-12-01
- Primary Completion
- 2006-05-01
More Related Trials
-
Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors
NCT00730821 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120
NCT00715403 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
NCT02952248 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors
NCT02171741 ·Status: COMPLETED ·Phase: PHASE1
-
Administration of BIIB028 to Subjects With Solid Tumors
NCT00725933 ·Status: COMPLETED ·Phase: PHASE1
-
An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours
NCT02182206 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.
NCT00998296 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of BBI503 in Adult Patients With Advanced Solid Tumors
NCT01781455 ·Status: COMPLETED ·Phase: PHASE1
-
Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors
NCT00618735 ·Status: COMPLETED ·Phase: PHASE1
-
BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit
NCT02211872 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1a/1b BGB-290 for Advanced Solid Tumors.
NCT02361723 ·Status: COMPLETED ·Phase: PHASE1
-
This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)
NCT03604445 ·Status: TERMINATED ·Phase: PHASE1
-
Weekly BI 836880 in Patients With Advanced Solid Tumors
NCT02689505 ·Status: COMPLETED ·Phase: PHASE1
-
To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours
NCT01951846 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors
NCT00345189 ·Status: COMPLETED ·Phase: PHASE1
-
BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours
NCT01169675 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread
NCT04147247 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
NCT02923349 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of ABT-414 in Subjects With Solid Tumors
NCT01741727 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
NCT02211859 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
NCT02697591 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors
NCT05217693 ·Status: RECRUITING ·Phase: PHASE1
-
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
NCT05163041 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
NCT05262530 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer
NCT01335269 ·Status: COMPLETED ·Phase: PHASE1